1. Home
  2. PAYS vs TOVX Comparison

PAYS vs TOVX Comparison

Compare PAYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$5.15

Market Cap

293.4M

ML Signal

HOLD

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.21

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYS
TOVX
Founded
2001
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.4M
7.3M
IPO Year
1998
2006

Fundamental Metrics

Financial Performance
Metric
PAYS
TOVX
Price
$5.15
$0.21
Analyst Decision
Strong Buy
Hold
Analyst Count
4
1
Target Price
$8.06
N/A
AVG Volume (30 Days)
277.5K
10.1M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$74,879,428.00
N/A
Revenue This Year
$41.20
N/A
Revenue Next Year
$20.62
N/A
P/E Ratio
$39.56
N/A
Revenue Growth
32.61
N/A
52 Week Low
$1.80
$0.17
52 Week High
$8.88
$2.03

Technical Indicators

Market Signals
Indicator
PAYS
TOVX
Relative Strength Index (RSI) 44.58 46.21
Support Level $5.11 $0.18
Resistance Level $5.38 $0.23
Average True Range (ATR) 0.18 0.02
MACD -0.02 0.00
Stochastic Oscillator 20.54 58.19

Price Performance

Historical Comparison
PAYS
TOVX

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: